Acknowledging the increasingly important role of whole-body MRI for directing patient care
in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical …

To date, the choice of therapy for an individual multiple myeloma patient has been based on
clinical factors such as age and comorbidities. The widespread evolution, validation, and …

PURPOSE 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed
tomography (CT) is currently the standard technique to define minimal residual disease …

In multiple myeloma spatial differences in the subclonal architecture, molecular signatures
and composition of the microenvironment remain poorly characterized. To address this …

Abstract Deciphering Multiple Myeloma evolution in the whole bone marrow is key to inform
curative strategies. Here, we perform spatial-longitudinal whole-exome sequencing …

The iliac crest is the sampling site for minimal residual disease (MRD) monitoring in multiple
myeloma (MM). However, the disease distribution is often heterogeneous, and imaging can …

Multiple myeloma (MM) is a plasma cell malignancy and the second most common
hematological neoplasm in adults, comprising 1.8% of all cancers. With an annual incidence …

Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of
clonal plasma cells in the bone marrow (BM). It is known that early genetic mutations in post …

Multiple myeloma (MM) exhibits significant heterogeneity in its presentation, genetics, and
treatment response. Despite therapeutic advances, some patients continue to relapse early …

The development of novel agents has transformed the treatment paradigm for multiple
myeloma, with minimal residual disease (MRD) negativity now achievable across the entire …